FDA international travel policy
International travel for FDA employees should be restricted to "essential" meetings in these non-"routine" times, Commissioner McClellan clarifies in March 24 memo. "Examples of 'essential' would include meetings where significant regulatory policy decisions will be made that will impact the Agency directly and where the policy decision would be expected to be different were FDA personnel not there to represent the Agency's position. 'Essential' does not include routine attendance at a conference, routine speeches, outreach, training, routine meetings of working groups, etc.," the memo says...
You may also be interested in...
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.